Suchergebnisse - "Masters, Gregory"

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update von Masters, Gregory A, Temin, Sarah, Azzoli, Christopher G, Giaccone, Giuseppe, Baker, Jr, Sherman, Brahmer, Julie R, Ellis, Peter M, Gajra, Ajeet, Rackear, Nancy, Schiller, Joan H, Smith, Thomas J, Strawn, John R, Trent, David, Johnson, David H

“… To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non-small-cell lung …”
Weitere Angaben

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events von Brahmer, Julie R, Abu-Sbeih, Hamzah, Ascierto, Paolo Antonio, Brufsky, Jill, Cappelli, Laura C, Cortazar, Frank B, Gerber, David E, Hamad, Lamya, Hansen, Eric, Johnson, Douglas B, Lacouture, Mario E, Masters, Gregory A, Naidoo, Jarushka, Nanni, Michele, Perales, Miguel-Angel, Puzanov, Igor, Santomasso, Bianca D, Shanbhag, Satish P, Sharma, Rajeev, Skondra, Dimitra, Sosman, Jeffrey A, Turner, Michelle, Ernstoff, Marc S

“… Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes …”
Volltext

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer von Bradley, Jeffrey D, Hu, Chen, Komaki, Ritsuko R, Masters, Gregory A, Blumenschein, George R, Schild, Steven E, Bogart, Jeffrey A, Forster, Kenneth M, Magliocco, Anthony M, Kavadi, Vivek S, Narayan, Samir, Iyengar, Puneeth, Robinson, Clifford G, Wynn, Raymond B, Koprowski, Christopher D, Olson, Michael R, Meng, Joanne, Paulus, Rebecca, Curran, Jr, Walter J, Choy, Hak

“… RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for …”
Weitere Angaben

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update von Hanna, Nasser, Johnson, David, Temin, Sarah, Baker, Jr, Sherman, Brahmer, Julie, Ellis, Peter M, Giaccone, Giuseppe, Hesketh, Paul J, Jaiyesimi, Ishmael, Leighl, Natasha B, Riely, Gregory J, Schiller, Joan H, Schneider, Bryan J, Smith, Thomas J, Tashbar, Joan, Biermann, William A, Masters, Gregory

“… Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer …”
Weitere Angaben

Fatty acid transport protein 2 reprograms neutrophils in cancer von Veglia, Filippo, Tyurin, Vladimir A., Blasi, Maria, De Leo, Alessandra, Kossenkov, Andrew V., Donthireddy, Laxminarasimha, To, Tsun Ki Jerrick, Schug, Zach, Basu, Subhasree, Wang, Fang, Ricciotti, Emanuela, DiRusso, Concetta, Murphy, Maureen E., Vonderheide, Robert H., Lieberman, Paul M., Mulligan, Charles, Nam, Brian, Hockstein, Neil, Masters, Gregory, Guarino, Michael, Lin, Cindy, Nefedova, Yulia, Black, Paul, Kagan, Valerian E., Gabrilovich, Dmitry I.

“… Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are pathologically activated neutrophils that are crucial for the regulation of immune responses …”
Volltext

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update von Hanna, Nasser H, Schneider, Bryan J, Temin, Sarah, Baker, Jr, Sherman, Brahmer, Julie, Ellis, Peter M, Gaspar, Laurie E, Haddad, Rami Y, Hesketh, Paul J, Jain, Dharamvir, Jaiyesimi, Ishmael, Johnson, David H, Leighl, Natasha B, Phillips, Tanyanika, Riely, Gregory J, Robinson, Andrew G, Rosell, Rafael, Schiller, Joan H, Singh, Navneet, Spigel, David R, Stabler, Janis O, Tashbar, Joan, Masters, Gregory

“… The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV …”
Weitere Angaben

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study von Goss, Glenwood D, O'Callaghan, Chris, Lorimer, Ian, Tsao, Ming-Sound, Masters, Gregory A, Jett, James, Edelman, Martin J, Lilenbaum, Rogerio, Choy, Hak, Khuri, Fadlo, Pisters, Katherine, Gandara, David, Kernstine, Kemp, Butts, Charles, Noble, Jonathan, Hensing, Thomas A, Rowland, Kendrith, Schiller, Joan, Ding, Keyue, Shepherd, Frances A

“… Survival of patients with completely resected non-small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not …”
Weitere Angaben

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study von Bradley, Jeffrey D, Paulus, Rebecca, Komaki, Ritsuko, Masters, Gregory, Blumenschein, George, Schild, Steven, Bogart, Jeffrey, Hu, Chen, Forster, Kenneth, Magliocco, Anthony, Kavadi, Vivek, Garces, Yolanda I, Narayan, Samir, Iyengar, Puneeth, Robinson, Cliff, Wynn, Raymond B, Koprowski, Christopher, Meng, Joanne, Beitler, Jonathan, Gaur, Rakesh, Curran, Walter, Choy, Hak

“… We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to …”
Volltext

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation von Kumar, Vinit, Cheng, Pingyan, Condamine, Thomas, Mony, Sridevi, Languino, Lucia R, McCaffrey, Judith C, Hockstein, Neil, Guarino, Michael, Masters, Gregory, Penman, Emily, Denstman, Fred, Xu, Xiaowei, Altieri, Dario C, Du, Hong, Yan, Cong, Gabrilovich, Dmitry I

“… Recruitment of monocytic myeloid-derived suppressor cells (MDSCs) and differentiation of tumor-associated macrophages (TAMs) are the major factors contributing …”
Weitere Angaben

Unique pattern of neutrophil migration and function during tumor progression von Patel, Sima, Fu, Shuyu, Mastio, Jerome, Dominguez, George A., Purohit, Abhilasha, Kossenkov, Andrew, Lin, Cindy, Alicea-Torres, Kevin, Sehgal, Mohit, Nefedova, Yulia, Zhou, Jie, Languino, Lucia R., Clendenin, Cynthia, Vonderheide, Robert H., Mulligan, Charles, Nam, Brian, Hockstein, Neil, Masters, Gregory, Guarino, Michael, Schug, Zachary T., Altieri, Dario C, Gabrilovich, Dmitry I.

“… Although neutrophils have been linked to the formation of the pre-metastatic niche, the mechanism of their migration to distant, uninvolved tissues has …”
Volltext

Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway von Alicea-Torres, Kevin, Sanseviero, Emilio, Gui, Jun, Chen, Jinyun, Veglia, Filippo, Yu, Qiujin, Donthireddy, Laxminarasimha, Kossenkov, Andrew, Lin, Cindy, Fu, Shuyu, Mulligan, Charles, Nam, Brian, Masters, Gregory, Denstman, Fred, Bennett, Joseph, Hockstein, Neil, Rynda-Apple, Agnieszka, Nefedova, Yulia, Fuchs, Serge Y., Gabrilovich, Dmitry I.

“… Myeloid-derived suppressor cells (MDSC) are pathologically activated neutrophils and monocytes with potent immune suppressive activity. These cells play an …”
Volltext

Precision Medicine in Lung Cancer Treatment von Shah, Dhaval R, Masters, Gregory A

“… Lung cancer remains second most common cancer in men and women in the United States. More than 50% of patients are diagnosed in the advanced stage …”
Weitere Angaben

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study von Pujol, Jean-Louis, De Pas, Tommaso, Rittmeyer, Achim, Vallières, Eric, Kubisa, Bartosz, Levchenko, Eugeny, Wiesemann, Sebastian, Masters, Gregory A, Shen, Robert, Tjulandin, Sergei A, Hofmann, Hans-Stefan, Vanhoutte, Nicolas, Salaun, Bruno, Debois, Muriel, Jarnjak, Silvija, De Sousa Alves, Pedro Miguel, Louahed, Jamila, Brichard, Vincent G, Lehmann, Frédéric F

“… Adjuvant platinum-based chemotherapy is standard treatment for surgically resected stage II to IIIA NSCLC, but the relapse rate is high. The preferentially …”
Weitere Angaben

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline von Singh, Navneet, Temin, Sarah, Baker, Jr, Sherman, Blanchard, Elizabeth, Brahmer, Julie R, Celano, Paul, Duma, Narjust, Ellis, Peter M, Elkins, Ivy B, Haddad, Rami Y, Hesketh, Paul J, Jain, Dharamvir, Johnson, David H, Leighl, Natasha B, Mamdani, Hirva, Masters, Gregory, Moffitt, Pamela R, Phillips, Tanyanika, Riely, Gregory J, Robinson, Andrew G, Rosell, Rafael, Schiller, Joan H, Schneider, Bryan J, Spigel, David R, Jaiyesimi, Ishmael A

“… To provide evidence-based recommendations updating the 2020 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage …”
Weitere Angaben

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis von Condamine, Thomas, Kumar, Vinit, Ramachandran, Indu R., Youn, Je-In, Celis, Esteban, Finnberg, Niklas, El-Deiry, Wafik S., Winograd, Rafael, Vonderheide, Robert H., English, Nickolas R., Knight, Stella C., Yagita, Hideo, McCaffrey, Judith C., Antonia, Scott, Hockstein, Neil, Witt, Robert, Masters, Gregory, Bauer, Thomas, Gabrilovich, Dmitry I.

“… Myeloid-derived suppressor cells (MDSCs) dampen the immune response thorough inhibition of T cell activation and proliferation and often are expanded in …”
Volltext

Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer von Kwak, Taekyoung, Wang, Fang, Deng, Hui, Condamine, Thomas, Kumar, Vinit, Perego, Michela, Kossenkov, Andrew, Montaner, Luis J., Xu, Xiaowei, Xu, Wei, Zheng, Cathy, Schuchter, Lynn M., Amaravadi, Ravi K., Mitchell, Tara C., Karakousis, Giorgos C., Mulligan, Charles, Nam, Brian, Masters, Gregory, Hockstein, Neil, Bennett, Joseph, Nefedova, Yulia, Gabrilovich, Dmitry I.

“… Here, we report that functional heterogeneity of macrophages in cancer could be determined by the nature of their precursors: monocytes (Mons) and monocytic …”
Volltext

Linking climate change and species invasion: an illustration using insect herbivores von WARD, NICOLA L, MASTERS, GREGORY J

“… Climate change and invasive species are two of the most important ecological issues facing the world today. Yet, to date these two factors have largely been …”
Volltext

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance) von Ready, Neal E, Pang, Herbert H, Gu, Lin, Otterson, Gregory A, Thomas, Sachdev P, Miller, Antonius A, Baggstrom, Maria, Masters, Gregory A, Graziano, Stephen L, Crawford, Jeffrey, Bogart, Jeffrey, Vokes, Everett E

“… To evaluate the efficacy of maintenance sunitinib after chemotherapy for small-cell lung cancer (SCLC). The Cancer and Leukemia Group B 30504 trial was a …”
Weitere Angaben

Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs von Mastio, Jérôme, Condamine, Thomas, Dominguez, George, Kossenkov, Andrew V, Donthireddy, Laxminarasimha, Veglia, Filippo, Lin, Cindy, Wang, Fang, Fu, Shuyu, Zhou, Jie, Viatour, Patrick, Lavilla-Alonso, Sergio, Polo, Alexander T, Tcyganov, Evgenii N, Mulligan, Jr, Charles, Nam, Brian, Bennett, Joseph, Masters, Gregory, Guarino, Michael, Kumar, Amit, Nefedova, Yulia, Vonderheide, Robert H, Languino, Lucia R, Abrams, Scott I, Gabrilovich, Dmitry I

“… We have identified a precursor that differentiates into granulocytes in vitro and in vivo yet belongs to the monocytic lineage. We have termed these cells …”
Weitere Angaben

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan von Gray, Jhanelle E, Heist, Rebecca S, Starodub, Alexander N, Camidge, D Ross, Kio, Ebenezer A, Masters, Gregory A, Purcell, W Thomas, Guarino, Michael J, Misleh, Jamal, Schneider, Charles J, Schneider, Bryan J, Ocean, Allyson, Johnson, Tirrell, Gandhi, Leena, Kalinsky, Kevin, Scheff, Ronald, Messersmith, Wells A, Govindan, Serengulam V, Maliakal, Pius P, Mudenda, Boyd, Wegener, William A, Sharkey, Robert M, Goldenberg, David M

“… We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small cell lung cancer (mSCLC) patients. Sacituzumab govitecan was studied in …”
Weitere Angaben